Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RONALD TODD PLOTT

Allopathic & Osteopathic Physicians Dermatology

NPI
1558569087
CMS profile
206083
Location
FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$19,232.86

111 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $14,800.00 5
Food and Beverage $2,479.38 100
Travel and Lodging $1,854.48 5
Education $99.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RONALD TODD PLOTT

NPI 1558569087 · CMS profile ID 206083

Allopathic & Osteopathic Physicians / Dermatology

FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558569087?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RONALD TODD PLOTT, NPI 1558569087, CMS profile ID 206083. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558569087?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RONALD TODD PLOTT, NPI 1558569087, CMS profile ID 206083. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558569087?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RONALD TODD PLOTT, NPI 1558569087, CMS profile ID 206083, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1558569087?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

111 matching records · $19,232.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 111 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–111 of 111.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $24.6202/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843475089 CMS
Janssen Biotech, Inc. $14.6702/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788385135 CMS
AbbVie Inc. $21.3602/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795662241 CMS
PFIZER INC. $21.1802/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832743291 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $24.2202/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851924609 CMS
Medtronic, Inc. $11.7902/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815645235 CMS
Janssen Biotech, Inc. $17.7302/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788385133 CMS
AbbVie Inc. $19.1801/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795662235 CMS
Galderma Laboratories, L.P. $1.5401/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855296331 CMS
AbbVie Inc. $21.0301/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795662229 CMS
Janssen Biotech, Inc. $13.8301/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788385131 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11,711.95 104
PY2020 $17,928.84 124
PY2021 $19,232.86 111
PY2022 $63,106.11 137
PY2023 $27,643.67 132
PY2024 $25,162.11 116
PY2025 $9,419.44 130

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,003,105.98 71
PY2024 Recipient $1,688.79 10
PY2024 Principal investigator $662,593.88 19
PY2021 Principal investigator $3,824.03 5
PY2019 Principal investigator $81,125.69 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $47,200.00 12/15/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132105
Principal investigator 1 SANOFI US SERVICES INC. $13,284.10 11/24/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132101
Principal investigator 1 PFIZER INC. $800.00 11/19/2025 Non-covered Recipient Entity
Stryde Consulting
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228739577
Principal investigator 1 SANOFI US SERVICES INC. $68,400.00 11/17/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132098
Principal investigator 1 SANOFI US SERVICES INC. $3,031.70 10/20/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226132095
Principal investigator 1 SANOFI US SERVICES INC. $7,100.00 10/14/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132088
Principal investigator 1 SANOFI US SERVICES INC. $41,000.00 09/22/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132084
Principal investigator 1 SANOFI US SERVICES INC. $14,704.10 09/15/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132079
Principal investigator 1 PFIZER INC. $750.00 09/03/2025 Non-covered Recipient Entity
Stryde Consulting
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228712986
Principal investigator 1 PFIZER INC. $1,050.00 09/03/2025 Non-covered Recipient Entity
Stryde Consulting
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228712988
Principal investigator 1 PFIZER INC. $250.00 09/03/2025 Non-covered Recipient Entity
Stryde Consulting
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228713072
Principal investigator 1 PFIZER INC. $2,100.00 09/03/2025 Non-covered Recipient Entity
Stryde Consulting
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228713074
Principal investigator 1 PFIZER INC. $10,000.00 09/03/2025 Non-covered Recipient Entity
Stryde Consulting
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228713370
Principal investigator 1 PFIZER INC. $350.00 09/03/2025 Non-covered Recipient Entity
Stryde Consulting
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228713456
Principal investigator 1 SANOFI US SERVICES INC. $32,400.00 08/25/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132075
Principal investigator 1 PFIZER INC. $2,290.00 08/11/2025 Non-covered Recipient Entity
Stryde Consulting
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228713368
Principal investigator 1 SANOFI US SERVICES INC. $5,161.70 08/11/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226132057
Principal investigator 1 SANOFI US SERVICES INC. $4,987.00 08/11/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132061
Principal investigator 1 SANOFI US SERVICES INC. $3,976.00 08/11/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132066
Principal investigator 1 Amgen Inc. $7,000.00 08/01/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC STRYDE RESEARCH
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) No dispute reported 06/30/2026 1246648802
Principal investigator 1 SANOFI US SERVICES INC. $32,600.00 07/14/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132006
Principal investigator 1 SANOFI US SERVICES INC. $9,485.60 07/14/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132008
Principal investigator 1 SANOFI US SERVICES INC. $4,153.50 07/14/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132011
Principal investigator 1 SANOFI US SERVICES INC. $3,031.70 07/07/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226132035
Principal investigator 1 SANOFI US SERVICES INC. $7,414.20 07/02/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226132016
Principal investigator 1 SANOFI US SERVICES INC. $32,600.00 06/16/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226131953
Principal investigator 1 SANOFI US SERVICES INC. $2,537.80 06/16/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131981
Principal investigator 1 SANOFI US SERVICES INC. $10,481.40 06/09/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226131950
Principal investigator 1 SANOFI US SERVICES INC. $2,499.02 05/19/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226131994
Principal investigator 1 SANOFI US SERVICES INC. $64,300.00 05/19/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132002
Principal investigator 1 SANOFI US SERVICES INC. $10,664.50 05/12/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131936
Principal investigator 1 SANOFI US SERVICES INC. $7,714.20 05/05/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226131907
Principal investigator 1 Amgen Inc. $59,170.41 04/24/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC STRYDE RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246648806
Principal investigator 1 Amgen Inc. $29,128.00 04/24/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC STRYDE RESEARCH
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246648810
Principal investigator 1 SANOFI US SERVICES INC. $49,200.00 04/14/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226131909
Principal investigator 1 SANOFI US SERVICES INC. $6,205.40 04/07/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226131897
Principal investigator 1 SANOFI US SERVICES INC. $21,786.40 04/02/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226131859
Principal investigator 1 SANOFI US SERVICES INC. $17,475.90 04/02/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131886
Principal investigator 1 SANOFI US SERVICES INC. $19,307.55 04/02/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226131894
Principal investigator 1 SANOFI US SERVICES INC. $4,574.20 03/24/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226131836
Principal investigator 1 SANOFI US SERVICES INC. $34,400.00 03/24/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226131856
Principal investigator 1 SANOFI US SERVICES INC. $25,486.50 03/10/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131870
Principal investigator 1 SANOFI US SERVICES INC. $5,090.70 03/10/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226131890
Principal investigator 1 SANOFI US SERVICES INC. $9,000.00 02/24/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131735
Principal investigator 1 SANOFI US SERVICES INC. $5,558.00 02/24/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131817
Principal investigator 1 SANOFI US SERVICES INC. $3,939.00 02/24/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131873
Principal investigator 1 SANOFI US SERVICES INC. $1,625.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131723
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131727
Principal investigator 1 SANOFI US SERVICES INC. $1,250.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131732
Principal investigator 1 SANOFI US SERVICES INC. $1,125.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131741
Principal investigator 1 SANOFI US SERVICES INC. $1,375.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131745
Principal investigator 1 SANOFI US SERVICES INC. $1,125.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131749
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131754
Principal investigator 1 SANOFI US SERVICES INC. $23,000.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226131758
Principal investigator 1 SANOFI US SERVICES INC. $875.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131761
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131766
Principal investigator 1 SANOFI US SERVICES INC. $625.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131770
Principal investigator 1 SANOFI US SERVICES INC. $750.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131779
Principal investigator 1 SANOFI US SERVICES INC. $375.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131785
Principal investigator 1 SANOFI US SERVICES INC. $18,325.00 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226131790
Principal investigator 1 SANOFI US SERVICES INC. $7,895.50 02/18/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131882
Principal investigator 1 SANOFI US SERVICES INC. $6,063.40 02/10/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226131877
Principal investigator 1 SANOFI US SERVICES INC. $15,900.00 02/04/2025 Non-covered Recipient Entity
Skin Care Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145024
Principal investigator 1 Amgen Inc. $14,000.00 01/30/2025 Non-covered Recipient Entity
STRYDE RESEARCH EPIPHANY DERMATOLOGY
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) No dispute reported 06/30/2026 1246648814
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 01/27/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131802
Principal investigator 1 SANOFI US SERVICES INC. $2,550.00 01/27/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131807
Principal investigator 1 SANOFI US SERVICES INC. $750.00 01/27/2025 Non-covered Recipient Entity
Stryde Consulting Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226131813
Principal investigator 1 SANOFI US SERVICES INC. $24,385.00 01/21/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226131775
Principal investigator 1 SANOFI US SERVICES INC. $26,400.00 01/21/2025 Non-covered Recipient Entity
Stryde Consulting Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226131793
Principal investigator 1 Amgen Inc. $53,321.99 01/07/2025 Non-covered Recipient Entity
EPIPHANY DERMATOLOGY
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246641271
Principal investigator 1 Amgen Inc. $53,251.51 01/02/2025 Non-covered Recipient Entity
STRYDE RESEARCH EPIPHANY DERMATOLOGY
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246648818

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2022 Amount invested $0.00 1
PY2022 Value of interest $61,680.00 1
PY2021 Amount invested $275,000.00 1
PY2021 Value of interest $102,750.00 1
PY2020 Amount invested $275,000.00 1
PY2020 Value of interest $99,000.00 1
PY2019 Amount invested $175,000.00 1
PY2019 Value of interest $58,000.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2019–2022

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2022 Medimetriks Pharmaceuticals, Inc. $0.00 $61,680.00 Dr. Platt has 75,000 shares at $0.8224 per share. Cert.#(s) 134 (25,000 sh); 141 (25,000 sh); 173 (25,000 sh). Physician Covered Recipient No dispute reported 06/30/2026 885272171
PY2021 Medimetriks Pharmaceuticals, Inc. $275,000.00 $102,750.00 HCP OWNS 75,000 SHARES. Physician Covered Recipient No dispute reported 06/30/2026 803531619
PY2020 Medimetriks Pharmaceuticals, Inc. $275,000.00 $99,000.00 Shares of Stock Physician Covered Recipient No dispute reported 06/30/2026 746592249
PY2019 Medimetriks Pharmaceuticals, Inc. $175,000.00 $58,000.00 Shares of Stock Physician Covered Recipient No dispute reported 06/30/2026 703279819